Heavy Metal Index

Effects of Inorganic Arsenic in Infant Rice Cereal on Children's Neurodevelopment

6 min read

Source access

Publication
Abt Associates report prepared for Healthy Babies Bright Futures
Year
2017
Authors
Chiger A; Lynch MT
Source type
agency report
License
publicly distributed

Chiger & Lynch (Abt/HBBF) 2017 — IQ loss + monetized benefits of reducing iAs in infant rice cereal

This is a commissioned report from Abt Associates to Healthy Babies Bright Futures (HBBF), December 2017, examining inorganic arsenic exposures from infant rice cereal and U.S. rice consumption patterns and estimating IQ loss + monetized benefit of reduction scenarios. The methodology applies established concentration-response functions (CRFs) from Wasserman et al. 2004, Wasserman et al. 2007, Hamadani et al. 2011, and the CalEPA 2008 / MassDEP 2011 RfDs to quantify IQ losses across U.S. children aged 0-6 under various exposure scenarios, then monetizes those losses using benefit-cost frameworks consistent with regulatory standard-setting. The headline findings: replacing all rice and rice products with arsenic-free alternatives in U.S. children 0-6 would avoid more than 9 million IQ points/year and generate 1.2-1.8 billion in additional earnings. This report is the canonical NGO/policy reference for cost-benefit arguments around FDA’s 100 ppb iAs action level for infant rice cereal and is heavily cited by HBBF, state regulators, and advocacy litigation.

Key numbers

U.S. population scope: children aged 0-6 (approximately 24 million), with detailed exposure-modelling using NHANES, FITS, Karagas, and Carignan datasets.

Avoided-loss estimates (Executive Summary):

Intervention scenarioIQ points avoided/yearAdditional earnings/year
Replace all rice + rice products with arsenic-free>9 million$12-18 billion
Replace infant rice cereal only with arsenic-free~1 million$1.2-1.8 billion

Concentration-response functions selected (Section 6.1):

  • Hamadani et al. 2011 — Bangladesh infant cohort, prenatal + early-life iAs vs childhood IQ
  • Wasserman et al. 2004 — Bangladesh, drinking water iAs vs 10-year-old IQ
  • CalEPA 2008 / Massachusetts DEP 2011 — RfD derivation for neurodevelopmental endpoints from these and related studies
  • Wasserman et al. 2007 — Bangladesh, drinking water iAs vs 6-year-old IQ + WPPSI score

Health-based limits compared (Section 4.2):

  • USEPA IRIS 1991 RfD for chronic oral iAs: 0.3 µg/kg-bw/day (dermal-effects-derived)
  • Tsuji et al. 2015 RfD for neurodevelopmental effects: a tighter value derived from the Hamadani 2011 + Wasserman 2007 BMDL10 endpoints (the report concludes Tsuji’s RfD is more appropriate for the infant/early-childhood window)
  • ATSDR 2007 MRL: 0.3 µg/kg-bw/day
  • Shibata et al. 2016 proposed MCL for iAs in infant rice cereal (cited as alternative to FDA’s 100 ppb)

Exposure scenario inputs (Section 3.2 + 3.3):

  • NHANES “What We Eat In America” 2009-2014 rice + rice product consumption
  • FITS 2008 + 2016 — Nestlé Feeding Infants and Toddlers Study, child-specific intake
  • Karagas et al. 2016 — New Hampshire birth cohort, infant urine iAs vs rice consumption
  • FDA risk assessment 2016 — iAs concentrations in infant rice cereal market basket
  • Xue et al. 2010 — earlier U.S. dietary iAs intake modelling
  • Carignan et al. 2016 — pregnant women cohort iAs intake vs rice consumption
  • Shibata et al. 2016 — infant rice cereal MCL derivation

Methods

This is a literature-synthesis + exposure-modelling + cost-benefit analysis report. No primary measurement.

Methodology framework (per the report’s Sections 4-6):

  1. Section 3: Compile published distributions of iAs concentrations in infant rice cereal (FDA 2016 + Karagas 2016 + other sources) and consumption rates (NHANES + FITS + Carignan).
  2. Section 4: Compare modelled exposure scenarios against the four cited health-based limits (USEPA IRIS 1991, Tsuji 2015, ATSDR MRL, Shibata 2016 MCL) to identify where current U.S. exposure exceeds each limit.
  3. Section 5: Literature review of arsenic-IQ association studies. Inclusion criteria: epidemiological design, child-cohort outcomes, quantifiable concentration-response. Discussion of confounders and limitations.
  4. Section 6: Apply selected CRFs (Hamadani 2011, Wasserman 2004/2007, CalEPA/MassDEP) to U.S. exposure scenarios to estimate per-child and nationwide IQ point losses. Monetize using established benefit-cost methodology in support of regulatory standards.

Appendix A: Review of literature on dimethylarsinic acid (DMA) health effects. Appendix B: Additional arsenic-IQ studies.

Speciation: iAs only. Total arsenic and DMA discussed in appendices for completeness but not used in CRFs.

Implications

Certification: For HMTc Cat 1 infant rice cereal row, this report is the canonical advocacy/policy reference that establishes:

  1. The $1.2-1.8B-per-year-in-avoidable-IQ-loss claim that HBBF uses in advocacy. HMTc certification of low-iAs infant rice cereal is a partial market intervention against this loss; brand-legal positioning around HMTc should explicitly cite Chiger 2017 as the cost-of-not-acting reference.

  2. The Tsuji 2015 neurodevelopmental RfD vs USEPA IRIS 1991 chronic-oral RfD distinction. The Tsuji RfD is more relevant for infant exposure modelling because it’s derived from the same cohorts (Hamadani 2011, Wasserman 2007) that document neurodevelopmental effects, not from the dermal/skin-lesion endpoint that IRIS 1991 uses. HMTc Cat 1 infant rice cereal thresholds should anchor on the Tsuji RfD for the toxicology basis, with the FDA 100 ppb action level cited as the regulatory-alignment ceiling.

  3. The CRF selection rationale (Section 6.1). Future Cat 1 standards work — and HMTc threshold derivation for other rice-containing Cat 1 rows — should pull the same CRFs cited here. This report is the convergence point for the policy-relevant scientific consensus.

  4. The “replace all rice products” scenario (9M IQ points/year, $12-18B) is the upper bound — informative for setting Cat 1 threshold ambition. HMTc’s market-ratcheting logic (CLAUDE.md Part 2: tighter than literature floor, by design) is justified by this analysis: even at full FDA-compliant rice (≤100 ppb), the U.S. is foregoing >9M IQ points/year because the avoidable iAs intake is non-zero.

Courses: Excellent reference for an HMTc course module on benefit-cost analysis of food-safety standards. The Tsuji RfD vs IRIS 1991 RfD comparison is a teachable example of how neurodevelopmental endpoints can be more stringent than chronic-oral endpoints.

App: For the consumer-app risk communication, the Chiger 2017 framing — “IQ points avoided per year” — translates well to a per-child estimate that consumers can act on. A child consuming infant rice cereal at 50 ppb iAs vs 10 ppb iAs has measurable IQ-loss probability differential, per the cited CRFs.

Microbiome: Not addressed (this is an exposure + dose-response report, not mechanism).

Wiki pages updated on ingest